Pharmacogenetic Phenotyping and Genotyping
- 20 Downloads
Enzymes that metabolise foreign compounds exhibit a large degree of interindividual variability in their levels of expression. In a number of instances this variability can be accounted for by null or variant alleles resulting from mutations in genes encoding these enzymes. Human variability in drug metabolism can be determined by biochemical and pharmacological assays. In cases where a genetic change has been characterised, polymerase chain reaction techniques have been developed to diagnose metabolism deficiencies.
Genetic differences in certain foreign compound metabolising enzymes such as glutathione S-transferase M1, N-acetyltranferase 2 and CYP2D6 have been shown to be associated with risk for developing environmentally and occupationally based diseases such as cancer. Drug therapy can also be compromised by the existence of genetic deficiencies in a number of enzymes, including CYP2D6. It is anticipated that determination of an individual’s drug metabolism capabilities by use of phenotyping and genotyping tests will allow for more rational and safe drug administration protocols.
KeywordsOmeprazole Poor Metabolisers Debrisoquine Thiopurine Polymerase Chain Reaction Test
Unable to display preview. Download preview PDF.
- Aoyama T, Yamano S, Waxman DJ, Meyer UA, Fisher V, et al. Cytochrome P450 hPCN3, a novel P450 III? gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. Journal of Biological Chemistry 264: 10388–10395, 1989PubMedGoogle Scholar
- Atkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of serum paraoxonase/arylesterase: glutamine or arginine at position 191, for respective A or B allozymes. American Journal of Human Genetics 52: 598–608, 1993Google Scholar
- Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, et al. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. Journal of the National Cancer Institute 85: 1159–1164, 1993PubMedCrossRefGoogle Scholar
- Cholerton S, Smith RL. Human pharmacogenetics of nitrogen oxidations. In Hlavica & Damani (Eds) N-oxidation of drugs: biochemistry, pharmacology, toxicology, pp. 107–131, Chapman & Hall, London, 1991Google Scholar
- Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology 4: 158–178, 1991Google Scholar
- Hadadi AFA, Coulter CEA, Idle JR. Phenotypical deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Research 48: 5167–5171, 1988Google Scholar
- Hall MCS, Gregory WL, Idle JR. Pharmacogenetics: can the therapeutic key objective be accomplished. In Weatman & Seymour (Eds) Horizons in medicine, McGraw-Hill, London, in press, 1994Google Scholar
- Kalow W. Pharmacogenetics: heredity and the response to drugs, W.B. Saunders, Philadelphia, 1962Google Scholar
- La Du BN. Human serum paraoxonase/arylesterase. In Kalow (Ed.) Pharmacogenetics of drug metabolism, pp. 51–91, Pergamon Press Inc., New York, 1992Google Scholar
- Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Deficient (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics, in press, 1994Google Scholar
- Rost KL, Brosicke H, Brockmoller J, Scheffler M, Helge H, et al. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clinical Pharmacology and Therapeutics 52: 170–180, 1992PubMedCrossRefGoogle Scholar
- Seidergard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione S-transferase active on trans-stilbene oxide are due to gene deletion. Proceedings of the National Academy of Sciences of the United States of America 45: 7293–7297, 1988CrossRefGoogle Scholar
- Weber WW. The acetylator genes and drug response, Oxford University Press, New York, 1987Google Scholar
- Whittaker M. Cholinesterase, Karger, Basel, 1986Google Scholar
- Wilkinson G, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In Kalow (Ed.) Pharmacogenetics of drug metabolism, pp. 657–685, Pergamon Press Inc., New York, 1992Google Scholar
- Yue QY, Svensson JO, Alm C, Sjöqvist F, Säwe J. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. British Journal of Clinical Pharmacology 28: 539–545, 1989Google Scholar